MedPath

DOJOLVI

These highlights do not include all the information needed to use DOJOLVI safely and effectively. See full prescribing information for DOJOLVI. DOJOLVI (triheptanoin) oral liquid Initial U.S. Approval: 2020

Approved
Approval ID

4cfeb8bd-143e-4dd7-bc34-b0bcda02460d

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Jun 19, 2023

Manufacturers
FDA

Ultragenyx Pharmaceutical Inc.

DUNS: 962892019

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Triheptanoin

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code69794-050
Application NumberNDA213687
Product Classification
M
Marketing Category
C73594
G
Generic Name
Triheptanoin
Product Specifications
Route of AdministrationORAL
Effective DateJune 19, 2023
FDA Product Classification

INGREDIENTS (1)

TRIHEPTANOINActive
Quantity: 0.96 g in 1 mL
Code: 2P6O7CFW5K
Classification: ACTIB

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

DOJOLVI - FDA Drug Approval Details